Archive for the Home Page Category

Nanoscope Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nanoscope Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nanoscope Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

DALLAS, TX (November 22, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that management will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, in New York.

Chief Executive Officer, Sulagna Bhattacharya, and Chief Medical Officer, Aaron Osborne will provide a company update on Nanoscope’s clinical and corporate activities on Thursday, December 1, at 2:10 PM Eastern Time in the Harlem Track of the Lotte New York Palace. Nanoscope leadership will be available for in-person meetings at the conference on Thursday, December 1.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope Therapeutics to Host Clinical Perspectives Panel to Discuss MCO-010 and the Treatment Landscape for Retinitis Pigmentosa and Stargardt Disease

Nanoscope Therapeutics to Host Clinical Perspectives Panel to Discuss MCO-010 and the Treatment Landscape for Retinitis Pigmentosa and Stargardt Disease

Nanoscope Therapeutics to Host Clinical Perspectives Panel to Discuss MCO-010 and the Treatment Landscape for Retinitis Pigmentosa and Stargardt Disease

Webcast to be held on Thursday, November 17th from 4:30-5:30 pm ET

DALLAS, TX. – November 10, 2022 – Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, will host a clinical perspectives event on Thursday, November 17, 2022 from 4:30 – 5:30 p.m. ET. The event will focus on Nanoscope’s lead candidate, MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy, and its potential role in treating retinitis pigmentosa (RP) and Stargardt disease, two inherited retinal diseases that are leading causes of blindness in the working-age population.

Sulagna Bhattacharya, Co-Founder and CEO of Nanoscope Therapeutics, will introduce the event and provide an introduction to MCO-010. This will be followed by presentations on the treatment landscape, unmet medical need, and a Q&A panel with renowned experts in RP and Stargardt disease, including:

Stephen Tsang, M.D., Ph.D.
László Bitó Professor, Ophthalmology, Pathology and Cell Biology, Institute of Human Nutrition, and Columbia Stem Cell Initiative, Columbia University and Co-director for Stem Cells, Genome Engineering and Regenerative Medicine Course

Victor H. Gonzalez, M.D.
Founder/Chief Executive, Valley Retina Institute, McAllen, TX. Dr. Gonzalez is also affiliated with Valley Baptist Medical Center-Harlingen, South Texas Health System, Harlingen Medical Center, Mission Regional Medical Center, Rio Grande Regional Hospital, Knapp Medical Center, and Doctor’s Hospital at Renaissance.

Samar Mohanty, Ph.D., Co-Founder & President, and Aaron Osborne, MBBS, Chief Medical Officer & Chief Development Officer of Nanoscope Therapeutics will also participate in the panel discussion.

Webcast Details
A live webcast of the event will be available on the Events page of the Nanoscope Therapeutics website and may be accessed through https://nanoscope-therapeutics-conference-call.open-exchange.net/.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Nanoscope Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

 

Nanoscope Therapeutics Expands Clinical and CMC Leadership Team with Gene Therapy Pharma Experience

Nanoscope Therapeutics Expands Clinical and CMC Leadership Team with Gene Therapy Pharma Experience

Nanoscope Therapeutics Expands Clinical and CMC Leadership Team with Gene Therapy Pharma Experience

Dallas, TX (Nov 7, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that the Company has expanded its clinical and Chemistry, Manufacturing and Controls (CMC) team with the appointments of Jean Chang, as VP of Clinical Operations and Victor Adeniyi as Senior Director of CMC.

“We are excited to welcome Jean and Victor, both experienced biopharmaceutical leaders in gene therapy, to the Nanoscope team, and we look forward to the integral roles they will play in bolstering our clinical and CMC capabilities,” said Sulagna Bhattacharya, CEO of Nanoscope. “As we make steady progress with our clinical trials, their expertise will help support the continued advancement of our optogenetic gene therapies to restore vision in millions of people blinded by retinal diseases.”

Ms. Chang brings more than 20 years of experience in clinical operations and project management resulting in successful clinical trials in various therapeutic areas including CNS, cardiorenal, hematology, oncology, and ophthalmology. Previously, she served as Executive Director of Clinical Operations at Catalyst Biosciences, and Senior Director, Clinical Operations at Adverum Biotechnologies. Ms. Chang holds a B.S. in Medical Technology from China Medical University in Taiwan and an M.S. in Immunology from Wayne State University in Michigan.

Mr. Adeniyi has a decade of experience in cGMP manufacturing of biologics, including cell and gene therapy, leading successful manufacturing of clinical trial materials. Previously, he served as Head of Manufacturing and Tech Transfer at UT Southwestern Medical Center and manufacturing expert at Novartis Pharmaceuticals. Mr. Adeniyi also brings extensive experience in cGMP manufacturing while leading teams at Lonza, and Fujifilm Diosynth Biotechnologies. He earned his M.S. in Biotechnology and M.B.A. from the University of Houston.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership

Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership

Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership

Charles River will manufacture both plasmid DNA and viral vectors for late phase clinical trials targeting degenerative ocular diseases with no known cure

WILMINGTON, Mass. & DALLAS, Tx. – October 18, 2022 – Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced a comprehensive manufacturing collaboration utilizing Charles River’s extensive contract development and manufacturing (CDMO) services in both plasmid DNA and viral vectors.

“We are excited to continue to support Nanoscope Therapeutics’ efforts in the production of gene therapies that are focused on restoring vision for people suffering from retinal degenerative diseases with no known cure. Their work is incredibly important to patients, and we look forward to continuing to serve as a partner,” said Kerstin Dolph, Corporate Senior Vice President of Biologics Solutions at Charles River.

“Nanoscope looks forward to working with Charles River to support our accelerated development program. We have high expectations for our program and are counting on Charles River leadership, resources and scale to deliver in this partnership,” said Anil Lalwani, Vice President of CMC at Nanoscope Therapeutics, Inc.

A Robust Manufacturing Collaboration
Through this partnership, Nanoscope will have access to established manufacturing platforms and multiple Charles River CDMO centers of excellence, leveraging a comprehensive range of services including but not limited to GMP cell banking, High Quality (HQ) and GMP-grade plasmid DNA manufacture, and GMP adeno-associated virus (AAV) production.

This gene therapy manufacturing partnership builds on Charles River’s acquisitions of Cognate BioServices, Cobra Biologics, and Vigene Biosciences in 2021 that expanded its comprehensive cell and gene therapy (C&GT) portfolio to span each of the major CDMO platforms – cell therapy, viral vector, and plasmid DNA production.

Treating Degenerative Retinal Diseases
Nanoscope Therapeutics is developing gene-agnostic, sight restoring Multi-Characteristic Opsin (MCO) optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. Nanoscope’s optogenetic therapy uses a proprietary AAV2 vector to deliver MCO genes into retinal cells to enable vision in different color environments. The therapy is administered as a single intravitreal injection for in-office delivery without the need for any other devices or interventions.

About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Nanoscope Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Charles River Investor Contact:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Media Contact:
Amy Cianciaruso
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com

 

Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa

Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa

Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Retinitis Pigmentosa

 

DALLAS, TX (October 10, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa (RP) via intravitreal injection.

“The FDA’s decision to grant FTD underscores the importance of MCO-010 to address a serious unmet need and validates its potential as an effective therapeutic for patients with RP,” said Sulagna Bhattacharya, CEO of Nanoscope. “We are proud to have the support of the FDA and look forward to collaboratively interacting with FDA to assess next steps in the clinical development and future regulatory review of MCO-010.”

In January 2022, 27 RP patients with advanced vision loss were enrolled in a multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010. Top line data from the clinical trial are expected in H1 2023.

In September of this year, enrollment was completed in the Phase 2 open-label STARLIGHT clinical trial (NCT05417126) of MCO-010 in patients with advanced vision loss due to Stargardt disease. Six-month data from the clinical trial are expected in H1 2023.

The FDA’s Fast Track designation is intended to facilitate the development and expedite the review of novel therapies to treat serious conditions for which there is unmet medical need. With the Fast Track designation, Nanoscope Therapeutics is eligible for more frequent regulatory meetings and communications with the FDA.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

SOURCE Nanoscope Therapeutics

Nanoscope Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

Nanoscope Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

Nanoscope Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

 

DALLAS, TX (September 30, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that management will present at Chardan’s 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, in New York.

Chief Executive Officer, Sulagna Bhattacharya, and Chief Medical Officer, Aaron Osborne will present a company update on Nanoscope clinical and corporate activities on Monday, October 3, at 5:00 PM Eastern Time in the Embassy room. Nanoscope leadership will be available for in-person meetings at the event on both Monday, October 3, and Tuesday, October 4.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

SOURCE Nanoscope Therapeutics

Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Nanoscope Therapeutics to Present at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

 

DALLAS, Sept. 26, 2022 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform at Eyecelerator during the American Academy of Ophthalmology (AAO) 2022 Annual Meeting, taking place Thursday, September 29, 2022, in Chicago, IL.

Pioneering Optogenetic Therapeutics and Optical Gene Delivery for Vision Restoration
Date and Time: Thursday, September 29, 2022; 2:51 p.m. CT
Location: McCormick Place Convention Center

In addition to highlighting the benefits of MCO gene therapy, Dr. Mohanty will profile Nanoscope’s Phase 2b RESTORE trial from its lead clinical program as well as introduce the Company’s groundbreaking non-viral laser-delivered MCO-020 gene therapy for geographic atrophy. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

SOURCE Nanoscope Therapeutics

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Six-month data from Phase 2 STARLIGHT trial expected in H1 2023

DALLASSept. 13, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the Phase 2 STARLIGHT trial are expected in H1 2023.

“We are excited by the therapeutic potential of MCO-010, supported by robust data from previous preclinical and clinical studies,” said Sulagna Bhattacharya, CEO of Nanoscope. “Completing the quick two-month enrollment of this Phase 2 trial, which will evaluate the safety and effects of a single intravitreal injection of MCO-010, brings us another major step forward in developing this novel therapy with broad therapeutic application.”

The Phase 2 STARLIGHT open-label trial (NCT05417126) enrolled six subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.  In this study, all subjects received the same single intravitreal dose of 1.2E11gc/eye of MCO-010 as used in the Company’s Phase 2b retinitis pigmentosa (RP) study.

“Stargardt disease is a blinding condition affecting adults and children alike. It is the most common macular dystrophy and has no established treatment,” said Byron Lam, MD, Robert Z. & Nancy J. Greene Chair and Professor of Ophthalmology at the University of Miami and principal investigator in the Phase 2 STARLIGHT trial. “MCO-010 has the potential to improve visual function in RP and Stargardt patients, and we look forward to seeing the data from this study.”

Nanoscope’s optogenetic therapy uses a proprietary AAV2 vector to deliver MCO genes into retinal cells to enable vision in different color environments. The therapy is administered as a single intravitreal injection for in-office delivery without the need for any other devices or interventions. MCO-010 has received orphan drug designations for RP and Stargardt disease from the FDA and is concurrently being evaluated in Nanoscope’s Phase 2b RESTORE trial in patients with RP, with trial results also expected in H1 2023.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

SOURCE Nanoscope Therapeutics

Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

Nanoscope Therapeutics to Present at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting

DALLASSept. 8, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Dr. Samarendra Mohanty, Co-Founder and President, will give a presentation on the clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform and participate in a panel titled “Gene Therapy for Ophthalmic Disorders – A Year in Review” at the 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting, taking place September 13-16, 2022 in Boston, MA.

Details for the presentation are as follows:

Exploring Ambient Light Activatable Optogenetics for Vision Restoration in Retinal Degenerative Diseases
Date and Time: Thursday, September 15, 20229:00-9:30 a.m. ET
Location: DoubleTree by Hilton Boston North Shore

In addition to highlighting the benefits of MCO gene therapy, Dr. Mohanty will detail Nanoscope’s Phase 2b RESTORE trial from its lead clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023. He will also participate in the panel on Wednesday, September 14, 20228:25-9:05 am ET.

Two other additional technical leaders of Nanoscope, Dr. Subrata Batabyal and Dr. Sanghoon Kim, will be featured in a pre-conference workshop highlighting non-viral spatially targeted, laser gene delivery to retina (details below). Nanoscope’s MCO-020 gene therapy program is based on targeted laser-delivery of optogenes to areas of geographic atrophy in advanced AMD patients, and currently undergoing IND-enabling studies.

Workshop A: Discussing the Use of Non-Viral Gene Delivery as a Therapeutic Modality to the Eye
Date and Time: Tuesday, September 13, 20228:30-11:00 am ET
Location: DoubleTree by Hilton Boston North Shore

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

 

Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference

Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference

Nanoscope Therapeutics to Present at Baird’s 2022 Global Healthcare Conference

DALLAS, Sept. 7, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that management will present at Baird’s 2022 Global Healthcare Conference on Wednesday, September 14, 2022, in New York.

Chief Executive Officer, Sulagna Bhattacharya, and Chief Medical Officer, Aaron Osborne will present a company update on Nanoscope clinical and corporate activities on Wednesday, September 14, at 12:15 PM Eastern Time in the Morgan Suite (Mezzanine Level). Nanoscope leadership will be available for in-person meetings at the event on both Tuesday, September 13, and Wednesday, September 14.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope Announces Presentations at the 22nd Euretina Congress

Nanoscope Announces Presentations at the 22nd Euretina Congress

Nanoscope Announces Presentations at the 22nd Euretina Congress

Results of Phase 2b RESTORE trial for retinitis pigmentosa and six-month data for Phase 2 STARLIGHT trial for Stargardt disease expected in H1 2023

DALLAS, TX (August 29, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that clinical development of its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in two presentations at the 22nd Euretina Congress, taking place September 1-4, 2022, in Hamburg, Germany and online.

Details for the presentations are as follows:

Development of Novel Endpoints for the Study of Multi-Characteristic Opsin Enabled Vision Restoration in Patients with Advanced Retinitis Pigmentosa; Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study
Presenter: Victor Hugo Gonzalez, M.D., Valley Retina Institute, McAllen, TX.
Session: IRD I
Date and Time: Thursday, September 1, 2022; 3:05 p.m. CEST
Location: Hall X1, Congress Centre Hamburg

Dr. Gonzalez will discuss Nanoscope’s Phase 2b RESTORE trial, its most advanced clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023.

52 Week Safety and Efficacy of Optogenetic Therapy for Vision Restoration in Retinitis Pigmentosa Patients
Presenter: SriniVas R. Sadda, M.D., President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA), David Geffen School of Medicine.
Session: IRD II
Date and Time: Friday, September 2, 2022; 3:29 p.m. CEST
Location: Hall X1, Congress Centre Hamburg

Dr. Sadda will discuss the safety and efficacy of intravitreal MCO Optogenetic Therapy for vision restoration in advanced retinitis pigmentosa patients in a Phase 1/2a study.

 

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope Therapeutics to Present at the Retina Forum 2022

Nanoscope Therapeutics to Present at the Retina Forum 2022

Nanoscope Therapeutics to Present at the Retina Forum 2022

DALLASAug. 26, 2022 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Aaron Osborne, Chief Medical Officer, will give a presentation on clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform and participate in a panel titled “Gene Therapy Platforms for Macular Disease – Are They Worth the Money?” at the Retina Forum, taking place August 31, 2022, in Hamburg, Germany and online as part of the Ophthalmology Futures Forums.

Details for the presentation are as follows:

Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration
Presenter: Aaron Osborne, MBBS, Nanoscope’s Chief Medical Officer
Date and Time: Wednesday, August 31, 20224:51 p.m. CEST
Location: The Fontenay Hotel

In addition to highlighting the benefits of MCO gene therapy, Dr. Osborne will detail Nanoscope’s Phase 2b RESTORE trial from its lead clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in H1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected H1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope Therapeutics to Move Corporate Headquarters to Dallas

Nanoscope Therapeutics to Move Corporate Headquarters to Dallas

Nanoscope Therapeutics to Move Corporate Headquarters to Dallas

Company focused on unique optogenetic gene therapy to treat blindness

DALLAS, Texas (August 16, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that it is moving its corporate headquarters to Trinity Towers, in the hub of the Dallas Medical District.

“Moving to Trinity Towers places us in the heart of the growing healthcare community in Dallas,” said Nanoscope Co-Founder and CEO, Sulagna Bhattacharya. “Rapid growth is expected for Nanoscope in 2023 and Trinity Towers provides an excellent space for our expanding team to collaborate.”

Nanoscope’s MCO-010 is an optogenetic therapy delivered as a one-time intravitreal eye injection in an office setting. The therapy uses proprietary vector and promoter technology to deliver the MCO transgene into retinal bipolar cells. These retinal cells become light sensitive, potentially enabling vision in normal light environments.

MCO-010 is currently being evaluated in two clinical trials in the US for the treatment of severe vision loss due to retinitis pigmentosa (RP) and due to Stargardt disease. The Phase 2b multi-center randomized RESTORE trial of MCO-010 for RP is fully enrolled and results are expected in Q1 2023. In addition, the Phase 2 STARLIGHT trial of MCO-010 for Stargardt disease is underway and 6-month data from this multi-center open label study are expected in Q1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in a Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for RP (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com

Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

 

DALLASJuly 25, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the first patient has been dosed in a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease.

“This trial represents the second indication for our vision restoring therapy for people blinded by rare inherited retinal degenerative diseases regardless of gene mutations,” said Sulagna Bhattacharya, CEO of Nanoscope. “Our RESTORE Phase 2b trial for Retinitis Pigmentosa patients has completed enrollment and results are expected in Q1 2023. There are no approved treatments for these debilitating conditions.”

The Phase 2 STARLIGHT open-label trial (NCT05417126) currently has active clinical sites in Texas and Florida and will enroll approximately six patients to receive the same MCO-010 dose of 1.2E11gc/eye as used in the Phase 2b Retinitis Pigmentosa (RP) study. Six-month safety and efficacy data are expected in Q1 2023. Stargardt disease is a progressive, inherited condition affecting children and adults. The condition results in damage to the macula, the central part of the retina responsible for central and detailed vision. Stargardt disease can be caused by several different gene mutations and is the second most common inherited retinal condition after RP.

“Existing experimental treatments for Stargardt primarily aim to slow progression of vision loss. For people who already have advanced vision loss, an optogenetics based approach, such as MCO-010, may have much greater potential to restore lost vision,” Aaron Osborne, CMO and CDO at Nanoscope added.

“MCO-010 offers new hope for individuals with Stargardt macular degeneration. Stargardt patients with severe degeneration typically lack sufficient light sensing photoreceptor neurons needed to qualify for experimental ABCA4 gene specific therapies. Optogenetic therapy may be able to treat a wider group of patients with Juvenile macular degeneration regardless of the status of their light sensing photoreceptor neurons,” said Stephen Tsang, MD, PhD, Laszlo Z. Bito Professor of Ophthalmology, Pathology and Cell Biology at Columbia University Irving Medical Center and advisor to Nanoscope Therapeutics.

Nanoscope’s MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive. It uses proprietary vector and promoter technology to deliver the MCO genes into retinal bipolar cells enabling vision in different color environments. The therapy involves a single intravitreal injection in a medical office setting.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

DALLAS, Texas (July 14, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that the Company was chosen for Breakthrough Technologies Award at OIS Retina Innovation Summit in New York. The award is granted to a single company that demonstrates groundbreaking technological innovation, selected by Medical and Industry Peers.

At the OIS Retina Innovation Summit’s Spotlight on Breakthrough Technologies session, Samarendra Mohanty, Ph.D., Co-Founder, President and Chief Scientific Officer of Nanoscope, gave a presentation on the Company’s Platform technologies on Multi-Characteristic Opsin (MCO) and non-viral laser gene delivery. He also shared progress on U.S. clinical trials of MCO-010 for retinitis pigmentosa and Stargardt disease.

“Amongst the many dedicated industry leaders in the retina space who attended the OIS Retina Innovation Summit, it is an honor for us to be recognized by OIS,” said Nanoscope’s Co-Founder and CEO, Sulagna Bhattacharya. “We are not only encouraged by the progress we are making in advancing our MCO gene therapy platform, but also by the recognition from our industry of our efforts to improve the standard of care for patients suffering from retinal degenerative diseases.”

Results from Nanoscope’s Phase 2b RESTORE trial for retinitis pigmentosa, its most advanced clinical program, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in Q1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:

Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting

Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting

Nanoscope’s Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting

Results of Phase 2b RESTORE trial for retinitis pigmentosa and six-month data for Phase 2 STARLIGHT trial for Stargardt disease expected in Q1 2023

DALLAS, July 12, 2022 /PRNewswire/ — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that clinical development of its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in two presentations at the 2022 Annual Scientific Meeting of the American Society of Retina Specialists (ASRS), taking place July 13 – 16, in New York City.

Details for the presentations are as follows:

Update on U.S. Clinical Trials of MCO-010 for Retinitis Pigmentosa and Stargardt Disease and Review of Nanoscope’s Non-viral Laser Gene Delivery Platform
Presenter: Samarendra Mohanty, Ph.D., Nanoscope Co-Founder, President and Chief Scientific Officer
Session: ASRS satellite OIS Retina Innovation Summit, Spotlight on Breakthrough Technologies
Date and Time: Wednesday, July 13, 2022; 4:15 p.m. – 5:15 p.m. ET
Location: Edison Ballroom

Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients with Advanced Retinitis Pigmentosa
Presenter: Peter Kaiser, M.D., FASRS, of the Cole Eye Institute in the Department of Ophthalmology at the Cleveland Clinic
Session: Dry AMD 3 Symposium
Date and Time: Saturday, July 16, 2022; 10:15 a.m. – 11:20 a.m. ET
Location: Javits Center

Dr. Kaiser, a Nanoscope adviser, will discuss Nanoscope’s Phase 2b RESTORE trial, its most advanced clinical program. RESTORE trial results, along with six-month data from the Phase 2 STARLIGHT trial for Stargardt disease, are expected in Q1 2023.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting

Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting

Nanoscope’s Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting

Results of Phase 2b RESTORE trial for retinitis pigmentosa and six-month data for Phase 2 STARLIGHT trial for Stargardt disease expected in Q1 2023

 

DALLAS, Texas (July 11, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that two executive team members will participate and present at the World Orphan Drug Congress, taking place July 11-13, at Hynes Center in Boston.

Details are as follows:

Gene-agnostic Optogenetic therapy for orphan diseases: Overcoming developmental challenges for retinal disease treatments
Presenter: Samarendra Mohanty, Ph.D., Nanoscope President and Chief Scientific Officer
Session: Advanced Therapies Manufacturing,
Date and Time: Tuesday, July 12, 2022; 11:35 a.m. – 11:55 a.m. ET

Dr. Mohanty will discuss Nanoscope’s gene-agnostic optogenetic platform to address need of several orphan diseases. He will also present non-viral laser gene delivery platform for overcoming limitations of viral vector based redosing and delivery of large gene payload. Randomized controlled RESTORE trial results from retinitis pigmentosa patients, along with six-month key data from the Phase 2 STARLIGHT trial from Stargardt patients, are expected in Q1 2023.

Launching of breakthrough products for rare diseases
Chairperson: Michael Marquez, Nanoscope Chief Financial Officer
Session: Advanced Therapies Commercial,
Date and Time: Wednesday, July 13, 2022; 11:05 a.m. – 12:35 p.m. ET

Mr. Marquez will chair a session where key industry leaders will make presentations on commercialization of breakthrough gene and regenerative medicine products for orphan and rare diseases in Global market.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer

Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer

Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer

Dallas, TX (July 05, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced the appointment of Michael Marquez as Chief Financial Officer. Mr. Marquez brings over 17 years of finance experience, including deep experience leading finance and growth strategies for companies in the ophthalmic space.

“Michael’s experience leading finance strategy and initiatives for ocular companies will be valuable as we progress our platform of optogenetic therapies to restore vision in sufferers of inherited retinal degenerative diseases. This appointment strengthens our management team and underscores our evolution as a company,” said Nanoscope’s Co-Founder and CEO, Sulagna Bhattacharya.

“I’m excited to join Nanoscope at this pivotal juncture in its development with its novel approach to treating retinal degenerative disease, supported by compelling data that has been generated thus far for our lead candidate, MCO-010. I believe a robust finance strategy is crucial for the success of any company, and I am looking forward to helping Nanoscope navigate through advanced clinical development and eventually towards commercialization,” said Mr. Marquez.

Mr. Marquez was most recently CFO of TearLab, an ophthalmic diagnostics company with a point-of-care osmolarity test to aid in the diagnosis of dry eye disease. Previously, he served as CFO of Global Surgical at Alcon Laboratories, a global medical company specializing in eye care products. Prior to Alcon, Mr. Marquez worked for Price Waterhouse Coopers serving tax and audit clients in the insurance and manufacturing sectors. He has a Master of Science in accounting from The University of Texas at Arlington and a Bachelor of Business Administration in accounting from The University of Texas at Austin. He is also a licensed Certified Public Accountant in Texas.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The Company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The Company has also initiated a Phase 2 trial of MCO therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA orphan drug designations for RP and Stargardt. The pipeline also includes therapy for GA.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs international conference on optogenetics. He is winner of 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.